Dr Jan Poolman | Head Bacterial Vaccine Discovery and Early Development
Janssen

Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen

Dr. Jan Poolman is Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics resistant bacteria. In his role Jan is also responsible for external partnerships and clinical studies. He holds this function since 2011.
 
Jan is also a member of the Advisory Board for the Tuberculosis Vaccine Initiative (TBVI), and a member of the Editorial Board for the Expert Review of articles for the journal Vaccines.
 
From 1986 until 1996, Jan was Head of Vaccines R&D at the National Institute for Public Health and the Environment in the Netherlands (RIVM) and later the Netherlands Vaccines Institute (NVI). In 1997 he moved to industry and was appointed Head & Vice-President Bacterial Vaccines R&D at GSK Biologicals in Belgium. During his tenure, he contributed to the licensure of several vaccines: DTPaHBIPVHib Infanrix-Hexa, DTPaHBIPV Pediarix, Tdap Boostrix, HibMenC-TT Menitorix, 10-valent pneumococcal conjugate Synflorix, HibMenCY-TT Menhibrix, and ACWY-TT Nimenrix.
 
Jan began his career at the University of Amsterdam (UvA) where he obtained a Master’s degree in Chemistry in 1975 and a PhD on Meningococcal Surface Structure in 1981. In 1982 he was awarded an NIH post-doctoral fellowship research position at the University of Washington in Seattle, USA. In 1983 Jan returned to the UvA as Assistant-Professor Bacteriology. He held this position until 1985.
 
In his career Jan published over 200 articles in peer-reviewed journals. All his publications can be found under poolman.j on www.gopubmed.com.

Appearances:



Day Three 12th October, Human @ 09:00

Chair’s opening remarks

Day Three 12th October, Human @ 11:20

Extraintestinal pathogenic E. coli: Challenges for vaccine development and clinical progress

back to speakers